Navigation Links
Abbott Completes Acquisition of STARLIMS Technologies
Date:3/22/2010

ABBOTT PARK, Ill., March 22 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that it has completed its $123 million acquisition of STARLIMS Technologies Ltd., a leader in laboratory information management systems.  

The acquisition provides Abbott with leading products and expertise to build its position in laboratory informatics, an emerging and rapidly growing field focused on helping to manage the increasing amount of data generated in laboratories. STARLIMS's advanced web-based software applications help laboratories efficiently store, retrieve and analyze data and are designed for a wide variety of laboratory environments operating across a number of scientific, industrial and clinical disciplines.  

"STARLIMS gives us access to innovative technologies and technical expertise for our long-term strategy in laboratory informatics," said Edward L. Michael, executive vice president, diagnostics products, Abbott. "The acquisition enables us to provide a common informatics framework across all of our diagnostics businesses and, equally important, will help accelerate STARLIMS's growth strategy in the non-diagnostics market segments it currently serves."

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

Abbott Forward Looking Statement

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2009, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

SOURCE Abbott

Back to top

RELATED LINKS
http://www.abbott.com

'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
2. Abbott Statement: ACCORD Lipid Results Support Treatment Guidelines for Fibrate Use
3. New Data Demonstrates Abbotts Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
4. Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer
5. Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy
6. Abbott to Present at Cowen and Company Annual Health Care Conference
7. Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
8. Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
9. Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer
10. Abbotts Ibis Technology Named One of the Top Innovations for 2009 by The Scientist
11. The Deal Names Abbott Top Dealmaker for Second Consecutive Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... The Rebound mobile app is poised to become a vital ... prescription drug addiction. The app empowers users to develop an ... their dosage in a safe, controlled manner while maximizing well-being. ... 100,000 people to sign up will enjoy 3 months of ... ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):